Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cytokinetics reported its third quarter 2025 results, highlighting key developments and strategic planning for its lead candidate, aficamten.</li><li>The company is actively preparing for the potential FDA approval of aficamten for obstructive hypertrophic cardiomyopathy (oHCM), with significant progress in commercial readiness and regulatory engagements.</li><li>On the regulatory front, Cytokinetics has conducted productive discussions with the FDA regarding aficamten's Risk Evaluation and Mitigation Strategies (REMS) program and labeling considerations.</li></ul>

Cytokinetics reported its third quarter 2025 results, highlighting key developments and strategic planning for its lead candidate, aficamten.The company is actively preparing for the potential FDA approval of aficamten for obstructive hypertrophic cardiomyopathy (oHCM), with significant progress in commercial readiness and regulatory engagements.On the regulatory front, Cytokinetics has conducted productive discussions with the FDA regarding aficamten's Risk Evaluation and Mitigation Strategies (REMS) program and labeling considerations.

Cytokinetics’ Global Strategy Raises Big Questions—Is the Company Ready for a Worldwide HCM Push?

<ul><li>Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges.</li><li>The company's focus remains on advancing its pipeline of muscle biology-focused therapies, particularly within cardiology.</li><li>A key development is the ongoing regulatory process for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).</li></ul>

Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges.The company's focus remains on advancing its pipeline of muscle biology-focused therapies, particularly within cardiology.A key development is the ongoing regulatory process for aficamten, a treatment for obstructive hypertrophic cardiomyopathy (oHCM).

Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?

<ul><li>Cytokinetics, Inc., a biotechnology company focused on muscle biology-driven therapeutics, delivered a mixed first quarter of 2025, characterized by both strategic progress and challenges primarily revolving around its lead candidate, aficamten.</li><li>Investment considerations should weigh the developments in its regulatory and clinical endeavors against its financial performance and market readiness activities.</li><li>From a regulatory perspective, Cytokinetics has faced a setback with the FDA's extension of the Prescription Drug User Fee Act (PDUFA) date for aficamten, shifting the action date to December 26, 2025.</li></ul>

Cytokinetics, Inc., a biotechnology company focused on muscle biology-driven therapeutics, delivered a mixed first quarter of 2025, characterized by both strategic progress and challenges primarily revolving around its lead candidate, aficamten.Investment considerations should weigh the developments in its regulatory and clinical endeavors against its financial performance and market readiness activities.From a regulatory perspective, Cytokinetics has faced a setback with the FDA's extension of the Prescription Drug User Fee Act (PDUFA) date for aficamten, shifting the action date to December 26, 2025.

Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth?

<ul><li>Cytokinetics has made significant regulatory progress regarding their lead candidate, aficamten, intended for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).</li><li>Regulatory filings, such as the New Drug Application (NDA) acceptance by the FDA and the validation of the Marketing Authorisation Application (MAA) by the European Medicines Agency, suggest a positive trajectory for aficamten's approval process in multiple markets, including the U.S., Europe, and China.</li><li>This expansion across global markets is further supported by partnerships with Sanofi for development in China and Bayer for Japan.</li></ul>

Cytokinetics has made significant regulatory progress regarding their lead candidate, aficamten, intended for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).Regulatory filings, such as the New Drug Application (NDA) acceptance by the FDA and the validation of the Marketing Authorisation Application (MAA) by the European Medicines Agency, suggest a positive trajectory for aficamten's approval process in multiple markets, including the U.S., Europe, and China.This expansion across global markets is further supported by partnerships with Sanofi for development in China and Bayer for Japan.

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness!

<ul><li>Cytokinetics Inc. reported its third quarter 2024 results, highlighting significant developments across its pipeline and commercial readiness efforts.</li><li>A notable achievement was the completion of the rolling submission and the new drug application to the FDA for aficamten, a cardiac myosin inhibitor targeting obstructive hypertrophic cardiomyopathy (HCM).</li><li>This represents a key milestone in Cytokinetics' efforts to bring potentially transformative therapies to market.</li></ul>

Cytokinetics Inc. reported its third quarter 2024 results, highlighting significant developments across its pipeline and commercial readiness efforts.A notable achievement was the completion of the rolling submission and the new drug application to the FDA for aficamten, a cardiac myosin inhibitor targeting obstructive hypertrophic cardiomyopathy (HCM).This represents a key milestone in Cytokinetics' efforts to bring potentially transformative therapies to market.

Cytokinetics Back In The Spotlight Amid Fresh Takeover Speculation: Why Big Pharma May Be Eyeing This Biotech Gem?

United States

Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company.  The Company is focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cytokinetics Inc (CYTK US)

Cytokinetics’ Global Strategy Raises Big Questions—Is the Company Ready for a Worldwide HCM Push?

Cytokinetics reported its third quarter 2025 results, highlighting key developments and strategic planning for its lead candidate, aficamten. The...

Baptista Research

Cytokinetics vs. Camzyos: Who Will Win the Battle for HCM Patients?

Cytokinetics presented its Q2 2025 earnings and strategic updates, which highlighted significant operational milestones and challenges. The...

Baptista Research

Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth?

Cytokinetics, Inc., a biotechnology company focused on muscle biology-driven therapeutics, delivered a mixed first quarter of 2025, characterized...

Baptista Research

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness!

Cytokinetics has made significant regulatory progress regarding their lead candidate, aficamten, intended for the treatment of obstructive...

Baptista Research

Cytokinetics Back In The Spotlight Amid Fresh Takeover Speculation: Why Big Pharma May Be Eyeing This Biotech Gem?

Cytokinetics Inc. reported its third quarter 2024 results, highlighting significant developments across its pipeline and commercial readiness...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)